Does the media refer more to ATRA or ORIC?

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 2 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.46 beat Atara Biotherapeutics' score of 0.37 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ATRA or INDP?

Atara Biotherapeutics currently has a consensus target price of $9.50, indicating a potential upside of 10.98%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Atara Biotherapeutics is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer RCKT or ATRA?

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 2 mentions for Atara Biotherapeutics. Rocket Pharmaceuticals' average media sentiment score of 0.60 beat Atara Biotherapeutics' score of 0.37 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ATRA or PRLD?

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 2 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.37 beat Prelude Therapeutics' score of 0.11 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CMPX or ATRA?

In the previous week, Compass Therapeutics had 13 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 15 mentions for Compass Therapeutics and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.37 beat Compass Therapeutics' score of -0.32 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Atara Biotherapeutics (ATRA) Competitors

$8.56 -0.37 (-4.14%)

As of 09/23/2026 04:00 PM Eastern

Compare

ATRA vs. ORIC, INDP, RCKT, PRLD, and CMPX

Should you buy Atara Biotherapeutics stock or one of its competitors? Atara Biotherapeutics's main competitors and comparable companies include Oric Pharmaceuticals (ORIC), Indaptus Therapeutics (INDP), Rocket Pharmaceuticals (RCKT), Prelude Therapeutics (PRLD), and Compass Therapeutics (CMPX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 10.98%. Oric Pharmaceuticals has a consensus price target of $20.18, suggesting a potential upside of 51.40%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Oric Pharmaceuticals' return on equity of -35.35% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

In the previous week, Oric Pharmaceuticals had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 2 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.46 beat Atara Biotherapeutics' score of 0.37 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.71	$32.69M	-$1.18	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Indaptus Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Atara Biotherapeutics had 2 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 2 mentions for Atara Biotherapeutics and 0 mentions for Indaptus Therapeutics. Atara Biotherapeutics' average media sentiment score of 0.37 beat Indaptus Therapeutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Indaptus Therapeutics	Neutral

Atara Biotherapeutics currently has a consensus target price of $9.50, indicating a potential upside of 10.98%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Atara Biotherapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Indaptus Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Atara Biotherapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Indaptus Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.71	$32.69M	-$1.18	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Atara Biotherapeutics beats Indaptus Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Rocket Pharmaceuticals presently has a consensus target price of $8.63, suggesting a potential upside of 185.60%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 10.98%. Given Rocket Pharmaceuticals' higher possible upside, equities analysts clearly believe Rocket Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.36
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rocket Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A
Atara Biotherapeutics	$120.77M	0.71	$32.69M	-$1.18	N/A

Rocket Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Rocket Pharmaceuticals' return on equity of -52.77% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Rocket Pharmaceuticals and 2 mentions for Atara Biotherapeutics. Rocket Pharmaceuticals' average media sentiment score of 0.60 beat Atara Biotherapeutics' score of 0.37 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rocket Pharmaceuticals beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Prelude Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Atara Biotherapeutics has higher revenue and earnings than Prelude Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.71	$32.69M	-$1.18	N/A
Prelude Therapeutics	$22.42M	15.34	-$99.50M	-$0.73	N/A

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Prelude Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Prelude Therapeutics' return on equity of -75.35% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential upside of 10.98%. Prelude Therapeutics has a consensus price target of $8.75, indicating a potential upside of 103.02%. Given Prelude Therapeutics' higher probable upside, analysts plainly believe Prelude Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Atara Biotherapeutics has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 2 articles in the media. Atara Biotherapeutics' average media sentiment score of 0.37 beat Prelude Therapeutics' score of 0.11 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Prelude Therapeutics beats Atara Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atara Biotherapeutics has higher revenue and earnings than Compass Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	247.89	-$66.49M	-$0.40	N/A
Atara Biotherapeutics	$120.77M	0.71	$32.69M	-$1.18	N/A

Compass Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Compass Therapeutics' return on equity of -38.71% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-38.71%	-34.72%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

In the previous week, Compass Therapeutics had 13 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 15 mentions for Compass Therapeutics and 2 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.37 beat Compass Therapeutics' score of -0.32 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Therapeutics presently has a consensus target price of $10.21, indicating a potential upside of 773.02%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 10.98%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.76
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Compass Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Summary

Compass Therapeutics beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$89.64M	$3.98B	$7.31B	$13.28B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-7.25	13.88	274.10	25.70
Price / Sales	0.71	1,437.48	672.61	90.85
Price / Cash	1.84	113.29	77.80	52.76
Price / Book	-1.60	15.45	10.48	6.32
Net Income	$32.69M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-11.84%	-1.68%	-0.68%	0.17%
1 Month Performance	-9.51%	-6.15%	-3.18%	-3.27%
1 Year Performance	-39.97%	30.67%	15.13%	5.58%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	2.3712 of 5 stars	$8.56 -4.1%	$9.50 +11.0%	-34.0%	$89.64M	$120.77M	N/A	330	News Coverage Positive News
ORIC Oric Pharmaceuticals	2.7236 of 5 stars	$12.65 +5.1%	$19.60 +54.9%	+27.2%	$1.25B	N/A	N/A	111	News Coverage Positive News Analyst Forecast
INDP Indaptus Therapeutics	0.2026 of 5 stars	$3.14 +13.4%	N/A	+21.2%	$369.08M	N/A	N/A	5
RCKT Rocket Pharmaceuticals	2.7776 of 5 stars	$3.43 +2.4%	$8.57 +149.9%	-2.6%	$367.74M	N/A	N/A	202
PRLD Prelude Therapeutics	2.5733 of 5 stars	$4.59 flat	$7.67 +67.0%	+318.4%	$366.30M	$22.42M	N/A	79

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, INDP, RCKT, PRLD, and CMPX

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Indaptus Therapeutics?

Summary

How does Atara Biotherapeutics compare to Rocket Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Prelude Therapeutics?

Summary

How does Atara Biotherapeutics compare to Compass Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, INDP, RCKT, PRLD, and CMPX

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Do analysts rate ATRA or ORIC?

Is ATRA or ORIC more profitable?

Which has more risk and volatility, ATRA or ORIC?

Does the media refer more to ATRA or ORIC?

Do institutionals and insiders have more ownership in ATRA or ORIC?

Which has higher valuation & earnings, ATRA or ORIC?

Summary

How does Atara Biotherapeutics compare to Indaptus Therapeutics?

Does the media refer more to ATRA or INDP?

Do analysts rate ATRA or INDP?

Is ATRA or INDP more profitable?

Which has more risk & volatility, ATRA or INDP?

Which has stronger earnings & valuation, ATRA or INDP?

Do institutionals & insiders hold more shares of ATRA or INDP?

Summary

How does Atara Biotherapeutics compare to Rocket Pharmaceuticals?

Do analysts prefer RCKT or ATRA?

Do institutionals and insiders have more ownership in RCKT or ATRA?

Which has more risk & volatility, RCKT or ATRA?

Which has higher valuation and earnings, RCKT or ATRA?

Is RCKT or ATRA more profitable?

Does the media prefer RCKT or ATRA?

Summary

How does Atara Biotherapeutics compare to Prelude Therapeutics?

Which has better valuation and earnings, ATRA or PRLD?

Do institutionals & insiders have more ownership in ATRA or PRLD?

Is ATRA or PRLD more profitable?

Do analysts prefer ATRA or PRLD?

Which has more volatility & risk, ATRA or PRLD?

Does the media refer more to ATRA or PRLD?

Summary

How does Atara Biotherapeutics compare to Compass Therapeutics?

Do institutionals & insiders believe in CMPX or ATRA?

Which has better earnings and valuation, CMPX or ATRA?

Is CMPX or ATRA more profitable?

Does the media prefer CMPX or ATRA?

Do analysts recommend CMPX or ATRA?

Which has more volatility and risk, CMPX or ATRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools